Clinical Trials Logo

Head and Neck Neoplasms clinical trials

View clinical trials related to Head and Neck Neoplasms.

Filter by:

NCT ID: NCT04843644 Not yet recruiting - Oral Mucositis Clinical Trials

Microbiota and Symptom Distress in Head and Neck Cancer Patients Receiving Radiotherapy

Start date: April 10, 2021
Phase: N/A
Study type: Interventional

The investigators plan to conduct a 3-year pioneering care research project for mucositis in cancer patients. These include: (1) an analysis of the incidence and severity of mucositis, severity, treatment methods, and treatment costs; (2) an RCT comparing the effectiveness of honey, Taiwan green propolis, and usual care in mucositis of cancer patients; (3) monitoring of related symptom changes using a smart bracelet device; (4) a measurement of IL-1, IL-6, IL-10, and TNF, Microbiota in saliva, Microbiota in stool and (4) modeling of the trend of mucositis for alertness and search of essential parameters of the complications.

NCT ID: NCT04842162 Recruiting - Clinical trials for Head and Neck Cancer

Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery

MAGNOLIA
Start date: December 15, 2020
Phase: Phase 2
Study type: Interventional

Assess the sensitivity of real-time near-infrared fluorescence imaging to detect microscopic residual disease in the operating room after a complete macroscopic surgical resection of head and neck cancers

NCT ID: NCT04840472 Suspended - Clinical trials for Head and Neck Cancer

Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer

Start date: March 30, 2021
Phase: Phase 1
Study type: Interventional

The primary purpose of the study is to assess the safety of 111In-panitumumab as a molecular imaging agent in patients with Head and Neck Squamous Cell Carcinoma. The secondary objective is to compare sensitivity and specificity of identifying sentinel lymph nodes by systemic injection of 111In-panitumumab prior to Day of Surgery versus conventional local injection with an optical dye at the time of surgery.

NCT ID: NCT04830488 Active, not recruiting - Clinical trials for Head and Neck Cancer

Body Image After Head and Neck Cancer Treatment

BIHNC
Start date: April 5, 2021
Phase: N/A
Study type: Interventional

This is a pilot study of the Body Image after Head and Neck Cancer Treatment Program [BIHNC]. It is a six-week, psychoeducational, web-based program that includes e-learning didactic modules and personal reflection activities for participants to complete.

NCT ID: NCT04823832 Completed - Clinical trials for Obstructive Jaundice

Endoscopic Versus Percutaneous Biliary Drainage for Resectable Pancreatic Head Cancer

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

Patients with potentially resectable pancreatic head cancer and high bilirubin level, were stratified into two equal groups according to the method of biliary drainage: endoscopic stenting or percutaneous drainage.

NCT ID: NCT04818099 Recruiting - Radiation Injuries Clinical Trials

Vortioxetine in the Treatment of Depression Associated With Head and Neck Cancers Undergoing Radiotherapy

Start date: October 10, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effects of vortioxetine, once daily (QD), on mood disorders and cognitive dysfunction in patients with head and neck cancers undergoing radiotherapy.

NCT ID: NCT04813172 Recruiting - Clinical trials for Head and Neck Cancer

Enhanced Care Coordination for Head and Neck Cancer Survivors

ECC
Start date: January 8, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effect of a multidimensional symptom management intervention on decreasing symptom burden and thus reducing hospital utilization in patients undergoing radiation with or without chemotherapy for head and neck cancer.

NCT ID: NCT04809792 Not yet recruiting - Clinical trials for Head and Neck Cancer

MR-Linac for Head and Neck SBRT

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

This study will evaluate the feasibility and safety of using MR-guided adaptive Head and Neck stereotactic radiotherapy (SBRT) at each fraction on the 1.5T MR-Linac.

NCT ID: NCT04805528 Recruiting - Clinical trials for Head and Neck Cancer

Study of Non-invasive Acupuncture-like Transcutaneous Electrical Nerve Stimulation (Altens) to Help Alleviate Xerostomia After Radiation Therapy for Cancers of the Head and Neck

Start date: March 10, 2022
Phase: N/A
Study type: Interventional

The purpose of this study would like to learn if acupuncture-like electrical therapy can be used in patients with head and neck cancer who have had radiation treatment to treat dry mouth.

NCT ID: NCT04804852 Recruiting - Sarcopenia Clinical Trials

Assessment of the Prevalence of Sarcopenia by CT Scan in Patients Diagnosed With Head & Neck Cancer

SARVADS 1
Start date: October 29, 2020
Phase:
Study type: Observational

Sarcopenia is defined by the reduction in skeletal muscle mass and physical performance. It results in a decrease in muscle strength, overall physical activity, walking and the development of balance disorders and falls. It is one of the natural consequences of aging and contributes to frailty and the appearance of geriatric syndrome (s) (Chandapasirt et al, 2015; Cruz-Jentoft et al, 2010). Its prevalence in patients with Head & Neck cancer is 39% (Hua et al, 2020) and is associated with an increase in postoperative complications (Achim et al, 2017; Bril et al, 2019), with greater toxicity of chemotherapy. (Wendrich et al, 2017) and reduced overall survival (Hua et al, 2020). It is measured by CT scan (assessment of muscle volume with respect to L3 using IMAGE J software) (Teigen et al, 2018) and by clinical tests (performance tests) (Swartz et al, 2016, Cruz-Jentoft et al, 2010). Several studies have shown a possible assessment of sarcopenia by measuring skeletal muscle mass with regard to C3 (Ufuk et al, 2019; Swartz et al, 2016). This trial aims to evaluate the prevalence of sarcopenia in head and neck cancer evaluated by CT at C3.